Heart failure & cardiomyopathiesRandomised controlled trial
Cost-Effectiveness of Remote Haemodynamic Monitoring by an Implantable Pulmonary Artery Pressure Monitoring Sensor (CardioMEMS-HF System) in Chronic Heart Failure in the Netherlands
- Cost-effectiveness analysis (Markov model) based on patient-level data of the MONITOR-HF randomised trial
- Dutch societal perspective
- lifetime horizon
Authors' conclusion
The current cost-effectiveness study suggests that remote haemodynamic monitoring with PA-guided therapy on top of standard care is likely to be cost-effective for patients with symptomatic moderate-to-severe HF in the Netherlands.
Study context
- Population
- Patients with chronic heart failure (HF) (NYHA class III and ≥1 previous HF hospitalization), the Netherlands
- Comparison
- Pulmonary artery (PA)-guided therapy vs standard of care
- Primary endpoint
- Incremental cost per QALY gained
- Follow-up
- Lifetime horizon
Primary result
As reported in the abstract
Incremental cost per QALY gained (Dutch societal perspective, lifetime horizon)
- base-case analysis
- incremental cost 12 121 €
- Incremental cost per quality-adjusted life year (QALY) gained (Dutch societal perspective, lifetime horizon)
- QALY gain 0.58 QALYs
- ICER €20 753 per QALY, below the Dutch willingness-to-pay threshold of €50 000 per QALY gained for HF
- 20 753
Original publication
Cost-Effectiveness of Remote Haemodynamic Monitoring by an Implantable Pulmonary Artery Pressure Monitoring Sensor (CardioMEMS-HF System) in Chronic Heart Failure in the Netherlands. Eur J Heart Fail. Published 1 April 2024. doi:10.1002/ejhf.3213
Summarised from the published abstract; every number is checked against it